Upfront Payments. Within ten (10) days of the Effective Date, Celgene shall pay Acceleron Twenty-Five Million U.S. Dollars ($25,000,000) as an upfront, non-creditable, nonrefundable fee, relating to the license grants set forth in Article 4.
Appears in 4 contracts
Samples: Collaboration, License and Option Agreement (Acceleron Pharma Inc), Collaboration, License and Option Agreement (Acceleron Pharma Inc), Collaboration, License and Option Agreement (Acceleron Pharma Inc)
Upfront Payments. Within Celgene shall make the following payments to Acceleron within ten (10) days of the Effective Date, Celgene shall pay Acceleron Twenty: (i) thirty-Five Million U.S. Dollars five million dollars ($25,000,00035,000,000) as an upfront, non-creditable, nonrefundable non-refundable fee, relating to the license grants set forth in Article 4, and (ii) ten million dollars ($10,000,000) as an upfront, non-creditable, non-refundable fee, relating to the option program set forth in Article 7.
Appears in 3 contracts
Samples: Collaboration, License and Option Agreement (Acceleron Pharma Inc), Collaboration, License and Option Agreement (Acceleron Pharma Inc), Collaboration, License and Option Agreement (Acceleron Pharma Inc)
Upfront Payments. Within ten (10) days of the Effective Date, Celgene shall pay Acceleron Twenty-Five Million U.S. Dollars ($25,000,000) as an upfront, non-creditable, nonrefundable non-refundable fee, relating to the license grants set forth in Article 4.
Appears in 1 contract
Samples: Collaboration, License and Option Agreement (Acceleron Pharma Inc)
